Drug Interactions Between Vitamin D, Vitamin C, Lenalidomide, and Daratumumab
There are no clinically significant drug interactions between vitamin D, vitamin C, lenalidomide, and daratumumab—these supplements can be safely taken concurrently with this multiple myeloma regimen without dose adjustments.
Evidence for Safe Concurrent Use
The combination of lenalidomide and daratumumab is extensively studied and FDA-approved, with no documented interactions with standard vitamin supplementation 1.
Daratumumab combined with lenalidomide and dexamethasone (DRd) is a standard regimen that has been evaluated in multiple phase 3 trials (POLLUX, MAIA, GRIFFIN) involving thousands of patients, with no restrictions on vitamin supplementation reported 2, 3, 4.
The POLLUX trial demonstrated that daratumumab plus lenalidomide-dexamethasone significantly improved progression-free survival (83.2% at 12 months vs 60.1% in controls) without any documented vitamin-related interactions 2.
The MAIA trial in transplant-ineligible patients showed 70.6% progression-free survival at 30 months with DRd versus 55.6% with lenalidomide-dexamethasone alone, with no vitamin supplementation contraindications 3.
Documented Adverse Effects of the Regimen (Unrelated to Vitamins)
The known toxicities of daratumumab-lenalidomide combinations are well-characterized and do not involve vitamin interactions 2, 3:
Neutropenia is the most common grade 3-4 adverse event (50-52% with daratumumab combinations vs 35-37% without) 2, 3.
Infusion reactions occur in approximately 48% of patients, predominantly with the first daratumumab infusion, and are grade 1-2 in severity 1.
Thrombocytopenia (12.7%), anemia (12.4%), and pneumonia (13.7%) are other documented toxicities 2, 3.
Lymphopenia and leukopenia occur more frequently with daratumumab-containing regimens 4.
Clinical Considerations for Vitamin Supplementation
Vitamin D and vitamin C supplementation is commonly used in multiple myeloma patients and does not interfere with the pharmacokinetics or pharmacodynamics of lenalidomide or daratumumab 5, 6.
Dexamethasone (routinely combined with lenalidomide and daratumumab) does not interact with standard vitamin supplementation 6.
Lenalidomide is safely combined with multiple agents including proteasome inhibitors, monoclonal antibodies, and alkylating agents without vitamin-related concerns 5, 7.
Important Monitoring Parameters (Not Vitamin-Related)
Focus monitoring on the known toxicities of the regimen itself 5, 2, 3:
Complete blood counts should be monitored regularly for cytopenias (neutropenia, thrombocytopenia, anemia).
Thromboprophylaxis with aspirin or therapeutic anticoagulation is mandatory for all patients on lenalidomide due to thrombosis risk 5, 8.
Herpes zoster prophylaxis with acyclovir or valacyclovir is required when proteasome inhibitors are added to the regimen 5, 8.
Infusion reaction premedication (antihistamines, antipyretics, corticosteroids) should be administered before daratumumab infusions 9, 2.
Critical Pitfall to Avoid
Do not attribute any adverse effects to vitamin supplementation when the documented toxicities of lenalidomide-daratumumab are well-established 9, 2. If cytopenias, infections, or other complications occur, these are related to the chemotherapy regimen itself, not vitamin interactions.